e-Drug3D
2069
SOTAGLIFLOZIN
INN
SOTAGLIFLOZIN
cas 1018899-04-1
CLASS
METABOLISM
SODIUM-GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITOR
SODIUM-GLUCOSE COTRANSPORTER 1 (SGLT1) INHIBITOR
ROUTE (list)
ORAL
ATC code
A10BK06
PK parameters
F 25 PERCENT
Tmax 2.1 HOUR
VD 9000 LITER
Cl 315 LITER / HOUR
PPB 93 PERCENT
t1/2 28 HOUR
Solubility
PRACTICALLY INSOLUBLE IN WATER
TARGET SODIUM-GLUCOSE COTRANSPORTER 2 (SGLT2)
SODIUM-GLUCOSE COTRANSPORTER 1 (SGLT1)
SODIUM-GLUCOSE COTRANSPORTER 1 (SGLT1)
PDB
8HG7 (STRUCTURE OF HUMAN SGLT2-MAP17 COMPLEX WITH SOTAGLIFLOZIN)
Ligand code = LFL (link to the list of PDB complexes)
Download experimental 3D coordinates of LFL with added hydrogens
Sodium,glucose cotransporter 2 UNIPROT P31639 SLC5A2
Sodium,glucose cotransporter 1 UNIPROT P13866 SLC5A1
Formula:
C21H25ClO5S
Calculated chemical properties:
MW 424.93
NB_atoms 28
XLogP 3.17
PSA 81.78
NB_HD 3
NB_HA 5
fsp3 0.43
Lipinski(0=no;1=yes) 1
NB_atoms 28
XLogP 3.17
PSA 81.78
NB_HD 3
NB_HA 5
fsp3 0.43
Lipinski(0=no;1=yes) 1
FDA
NDA 216203 (pdf not found) INN (SOTAGLIFLOZIN) INPEFA (LEXICON PHARMS INC) APPROVAL= AP YEAR= 2023 NEWMOLECULARENTITY
NDA 216203 (pdf not found) INN (SOTAGLIFLOZIN) INPEFA (LEXICON PHARMS INC) APPROVAL= AP YEAR= 2023 NEWMOLECULARENTITY